BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sarepta Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sarepta Therapeutics's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06138743-10769@assetmemo.bio
DTSTAMP:20261121T010440Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SRP-1003: Phase 1/2 readout est. (NCT06138743)
DESCRIPTION:SRP-1003\, phase 1/2.\nStudy: Study of SRP-1003 in Participants
  With Type 1 Myotonic Dystrophy\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/srp-1003#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06138743
URL:https://assetmemo.bio/drug/srp-1003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06131983-10768@assetmemo.bio
DTSTAMP:20261121T010440Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:SRP-1001: Phase 1/2 readout est. (NCT06131983)
DESCRIPTION:SRP-1001\, phase 1/2\, Facioscapulohumeral Muscular Dystrophy.\
 nStudy: Study of SRP-1001 in Adult and Adolescent Participants With Facios
 capulohumeral Muscular Dystrophy Type 1\nEstimated primary completion: 31 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/srp-10
 01#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6131983
URL:https://assetmemo.bio/drug/srp-1001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
